<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04789616</url>
  </required_header>
  <id_info>
    <org_study_id>REB21-0258</org_study_id>
    <nct_id>NCT04789616</nct_id>
  </id_info>
  <brief_title>The Canadian Maraviroc RCT To Augment Rehabilitation Outcomes After Stroke</brief_title>
  <acronym>CAMAROS</acronym>
  <official_title>The CAMAROS Trial: The Canadian Maraviroc RCT To Augment Rehabilitation Outcomes After Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Memorial University of Newfoundland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dalhousie University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Parkwood Hospital, London, Ontario</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Riverview Health Centre Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Dr. Miriam and Sheldon G. Adelson Medical Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Calgary</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CAMAROS trial is a randomized controlled phase II trial analyzing the effect of coupling&#xD;
      a C-C chemokine receptor 5 (CCR5) antagonist, Maraviroc (Celsentri), and exercise to improve&#xD;
      both upper and lower extremity recovery after a stroke.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After stroke, the combination of progressive skills practice in an adequate dose plus&#xD;
      exercise for fitness augments motor and cognitive outcomes. However, sensorimotor and&#xD;
      cognitive improvements often plateau after 12 weeks. There is an urgent need to find novel&#xD;
      methods to drive recovery and lessen limb paralysis. Drugs that might enhance learning or&#xD;
      neural repair, as well as other molecular and synaptic adaptations that occur during skills&#xD;
      training and fitness exercise, might extend that recovery curve, although to date only&#xD;
      fluoxetine has given any hint of this. Most trials have tested agents that modulate&#xD;
      neurotransmitters. Several very recent preclinical experiments and observational studies in&#xD;
      patients after stroke suggest that the commercially available medication, Maraviroc, may&#xD;
      augment skills learning during rehabilitation training especially during the first three&#xD;
      months after onset, by acting on unique molecular components for novel learning.&#xD;
&#xD;
      The CAMAROS trial is a randomized, placebo-controlled, blinded phase II trial evaluating the&#xD;
      efficacy of coupling Maraviroc (Celsentri) with exercise rehabilitation across multiple&#xD;
      Canadian sites in 120 stroke participants. Patients will begin their participation within 6&#xD;
      weeks of stroke onset. Both groups will receive an exercise program in addition to standard&#xD;
      of care rehabilitation, but only one group (the intervention group) will receive the active&#xD;
      drug Maraviroc.&#xD;
&#xD;
      Study participants will be evaluated at baseline, after 4 weeks of taking the drug/placebo,&#xD;
      after 8 weeks of taking the drug/placebo, and at 6-months post-stroke. While enrolled in the&#xD;
      study, participants will be required to take part in an 8 week, daily exercise program.&#xD;
      Evaluators and participants will be blind to the treatment administered. The trial is&#xD;
      constructed with randomization to remove selection and allocation biases and to ensure&#xD;
      greater validity in observed differences in the outcome measures.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2021</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Fugl-Meyer Upper Extremity Assessment Score</measure>
    <time_frame>Baseline (between 5 days and 6 weeks after stroke), after 4 weeks on drug/placebo, after 8 weeks on drug/placebo, and 6-months post-stroke</time_frame>
    <description>Difference in subscale scores on the Upper-Extremity Fugl-Meyer Assessment - both motor (max 66) and sensory (max 12) components. Higher scores indicate better outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in 10-Meter Walk Test Score</measure>
    <time_frame>Baseline (between 5 days and 6 weeks after stroke), after 4 weeks on drug/placebo, after 8 weeks on drug/placebo, and 6-months post-stroke</time_frame>
    <description>A performance measure used to assess walking speed in meters per second over a short distance. It can be used to determine functional mobility, gait, and vestibular function. Faster speed indicates better function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Action Research Arm Test (ARAT)</measure>
    <time_frame>Baseline (between 5 days and 6 weeks after stroke), after 4 weeks on drug/placebo, after 8 weeks on drug/placebo, and 6-months post-stroke</time_frame>
    <description>The ARAT assesses arm function to determine the quality of the arm movement, and the limitation of activity. The ARAT consists of 4 sub-tests; that examines and individual's grip, grasp, pinch and gross motor movement in order to determine upper extremity function. Objects of varying size, shape, and weight must be either grasped, handled or moved in a specific task in order to evaluate function. Low scores mean worse function with the minimum possible score being 0 and the highest possible score being 57 (normal function).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 Minute Walk Test</measure>
    <time_frame>Baseline (between 5 days and 6 weeks after stroke), after 4 weeks on drug/placebo, after 8 weeks on drug/placebo, and 6-months post-stroke</time_frame>
    <description>An assessment of ambulatory function by measuring the distance walked over a period of 6 minutes. Greater distance walked indicates better function.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Fugl-Meyer Lower Extremity Assessment Score</measure>
    <time_frame>Baseline (between 5 days and 6 weeks after stroke), after 4 weeks on drug/placebo, after 8 weeks on drug/placebo, and 6-months post-stroke</time_frame>
    <description>Fugl-Meyer Lower Extremity Assessment assesses motor and sensorimotor impairment in the lower extremities. Total score is between 0 and 34. Sub-scales include: proximal (0-18), knee/ankle (0-10) and coordination/speed (0-6). Higher scores indicate better performance. Sub-scale scores are summed to calculate total score.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Health Questionnaire 9 (PHQ-9)</measure>
    <time_frame>Baseline (between 5 days and 6 weeks after stroke), after 8 weeks on drug/placebo, and 6-months post-stroke</time_frame>
    <description>A 9-question measurement used to screen for the presence and severity of depression.</description>
  </other_outcome>
  <other_outcome>
    <measure>Stroke Aphasia Depression Questionnaire (SADQ)</measure>
    <time_frame>BaselineBaseline (between 5 days and 6 weeks after stroke), after 8 weeks on drug/placebo, and 6-months post-stroke, 8-week assessment, and 6-month assessment</time_frame>
    <description>A 10-item questionnaire completed by a caregiver to quickly assess depressive symptoms in stroke patients with aphasia. Higher scores indicate a greater likelihood of depression.</description>
  </other_outcome>
  <other_outcome>
    <measure>European Quality of Life Across 5 Domains (EQ-5D)</measure>
    <time_frame>Baseline (between 5 days and 6 weeks after stroke), after 8 weeks on drug/placebo, and 6-months post-stroke</time_frame>
    <description>A self-completion questionnaire used to assess health-related quality of life.</description>
  </other_outcome>
  <other_outcome>
    <measure>Stroke Impact Scale (SIS)</measure>
    <time_frame>Baseline (between 5 days and 6 weeks after stroke), after 8 weeks on drug/placebo, and 6-months post-stroke</time_frame>
    <description>Stroke-specific, self-report, health status measure. Assesses multiple domains on a 5-point Likert scale. Domains include: strength (4-20), hand function (5-25), activities of daily living/instrumental activities of daily living (10-50), mobility (9-45), communication (7-35), emotion (9-45), memory and thinking (7-35), and participation (8-40). An extra question asks that the patient rate on a scale from 0 - 100 how much they feel that he/she has recovered from his/her stroke. The 4 physical domains (strength, hand function, mobility and activities of daily living) can be summed together to create a single, physical dimension score (28-140) while all other domains should remain separate. Higher scores indicate better function.</description>
  </other_outcome>
  <other_outcome>
    <measure>National Institutes of Health Stroke Scale (NIHSS)</measure>
    <time_frame>Baseline (between 5 days and 6 weeks after stroke) and 6-months post-stroke</time_frame>
    <description>A 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. Higher scores indicate greater impairment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Montreal Cognitive Assessment (MoCA)</measure>
    <time_frame>Baseline (between 5 days and 6 weeks after stroke) and 6-months post-stroke</time_frame>
    <description>A cognitive screening test used to assess: short term memory, visuospatial abilities, executive functions, attention, concentration, working memory, language, and orientation to time and place. Higher scores indicate better function.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Maraviroc (Celsentri)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maraviroc (Celsentri) will be administered to this group. Participants will be administered a dose of 300mg to be taken twice per day for the duration of the exercise intervention (8 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>An over-encapsulated placebo, or &quot;sugar pill&quot; (so it appears identical to the trial drug) will be administered to this group. Participants will be administered the placebo identical to the 300mg maraviroc tablet for the duration of the exercise intervention (8 weeks).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maraviroc</intervention_name>
    <description>Half of the participants will take maraviroc for a period of 8 weeks.</description>
    <arm_group_label>Maraviroc (Celsentri)</arm_group_label>
    <other_name>Celsentri</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Exercise Program</intervention_name>
    <description>All participants will take part in an 8-week exercise program. While in-hospital, participants will undergo standard of care rehabilitation (estimated at 45 minutes each daily for PT &amp; OT) plus a supplementary upper extremity exercise program (Graded Repetitive Arm Supplementary Program (GRASP); estimated at 1 hour daily).&#xD;
After discharge from inpatient care, participants will complete an at-home supplementary upper and lower extremity exercise program. This program will include walking daily and daily practice using the GRASP program.</description>
    <arm_group_label>Maraviroc (Celsentri)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Half of the participants will take a placebo for a period of 8 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>&quot;Sugar&quot; Pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Primary ischemic anterior circulation stroke&#xD;
&#xD;
          2. Age â‰¥18 years&#xD;
&#xD;
          3. At least 5 days after stroke but within 6 weeks of stroke&#xD;
&#xD;
          4. Hemiparesis requiring inpatient rehabilitation&#xD;
&#xD;
          5. Assistance available for daily rehabilitation training practice and for transportation&#xD;
             when needed&#xD;
&#xD;
          6. Adequate language skills to understand the Informed Consent and retain information&#xD;
             during daily therapies&#xD;
&#xD;
          7. At least one of the following:&#xD;
&#xD;
               -  some shoulder abduction with gravity eliminated and visible extension in two or&#xD;
                  more digits OR&#xD;
&#xD;
               -  visible hip flexion or extension&#xD;
&#xD;
        Subgroup Stratification Criteria&#xD;
&#xD;
          1. For Upper Extremity Group:&#xD;
&#xD;
               -  Minimum Ability: MRC grade &gt;1 for shoulder abduction AND MRC grade &gt;1 for finger&#xD;
                  extensor on at least one digit&#xD;
&#xD;
               -  Maximum Ability: Upper Extremity Fugl-Meyer Assessment Score &gt;56&#xD;
&#xD;
          2. For Lower Extremity Group:&#xD;
&#xD;
               -  Minimum Ability: requiring a 2-person assist&#xD;
&#xD;
               -  Maximum Ability: walking speed &lt;0.8m/s, no visible hip flexion or extension&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pre-stroke modified Rankin score &lt;2&#xD;
&#xD;
          2. Limited resources or illness that will not enable a return to living outside of a&#xD;
             facility&#xD;
&#xD;
          3. Cancer or other chronic illness that makes 3-year survival unlikely or will detract&#xD;
             from the ability to carry out exercise and skills practice&#xD;
&#xD;
          4. Existing pre-stroke serious disabling disease (e.g., Parkinson's disease, severe&#xD;
             traumatic brain injury, amputation)&#xD;
&#xD;
          5. Seizure related to stroke&#xD;
&#xD;
          6. Acute or chronic epilepsy&#xD;
&#xD;
          7. History of:&#xD;
&#xD;
               -  dementia&#xD;
&#xD;
               -  hepatitis or elevated hepatic transaminases or bilirubin&#xD;
&#xD;
               -  renal insufficiency or serum creatinine over 1.6&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sean Dukelow, MD PhD FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Calgary, Calgary, Alberta, Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruce Dobkin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, Los Angeles, California, USA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Craig Doram</last_name>
    <phone>403-210-8676</phone>
    <email>craig.doram@ucalgary.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mark Piitz</last_name>
    <phone>403-944-4050</phone>
    <email>mapiitz@ucalgary.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of British Columbia &amp; GF Strong Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 2G9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Courtney Pollock</last_name>
      <phone>604-827-1631</phone>
      <email>courtney.pollock@ubc.ca</email>
    </contact>
    <investigator>
      <last_name>Janice Eng, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Courtney Pollock, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jennifer Yao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Riverview Health Centre</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3L 2P4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Sepideh Pooyania</last_name>
      <phone>204-478-6219</phone>
      <email>spooyania@rhc.mb.ca</email>
    </contact>
    <investigator>
      <last_name>Sepideh Pooyania, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Barclay Ruth, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial University of Newfoundland</name>
      <address>
        <city>Saint John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1A 1E5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Maria Williams</last_name>
      <phone>709-777-2082</phone>
      <email>maria.williams@mun.ca</email>
    </contact>
    <investigator>
      <last_name>Michelle Ploughman, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jason McCarthy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dalhousie University</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 3J5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Melanie Dunlop</last_name>
      <phone>902-473-1401</phone>
      <email>Melanie.Dunlop@nshealth.ca</email>
    </contact>
    <investigator>
      <last_name>Marilyn Mackay-Lyons, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anita Mountain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Parkwood Institute</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6C 0A7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Mitch Longval</last_name>
      <phone>519-646-6100</phone>
      <phone_ext>42739</phone_ext>
      <email>Mitch.longval@sjhc.london.on.ca</email>
    </contact>
    <investigator>
      <last_name>Robert Teasell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Ellen Cohen</last_name>
      <phone>416-480-6100</phone>
      <phone_ext>85406</phone_ext>
      <email>ecohen@sri.utoronto.ca</email>
    </contact>
    <investigator>
      <last_name>Bradley MacIntosh, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandra Black, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto Rehabilitation Institute - University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2A2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Evan Foster</last_name>
      <phone>416-597-3422</phone>
      <phone_ext>3362</phone_ext>
      <email>Evan.Foster@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Mark Bayley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>https://viivhealthcare.com/content/dam/cf-viiv/viiv-healthcare/en_CA/pdf/celsentri.pdf.pdf</url>
    <description>Product Monograph for Celsentri (Maraviroc)</description>
  </link>
  <reference>
    <citation>Ben Assayag E, Korczyn AD, Giladi N, Goldbourt U, Berliner AS, Shenhar-Tsarfaty S, Kliper E, Hallevi H, Shopin L, Hendler T, Baashat DB, Aizenstein O, Soreq H, Katz N, Solomon Z, Mike A, Usher S, Hausdorff JM, Auriel E, Shapira I, Bornstein NM. Predictors for poststroke outcomes: the Tel Aviv Brain Acute Stroke Cohort (TABASCO) study protocol. Int J Stroke. 2012 Jun;7(4):341-7. doi: 10.1111/j.1747-4949.2011.00652.x. Epub 2011 Nov 2.</citation>
    <PMID>22044517</PMID>
  </reference>
  <reference>
    <citation>Ben Assayag E, Shenhar-Tsarfaty S, Korczyn AD, Kliper E, Hallevi H, Shopin L, Auriel E, Giladi N, Mike A, Halevy A, Weiss A, Mirelman A, Bornstein NM, Hausdorff JM. Gait measures as predictors of poststroke cognitive function: evidence from the TABASCO study. Stroke. 2015 Apr;46(4):1077-83. doi: 10.1161/STROKEAHA.114.007346. Epub 2015 Feb 12.</citation>
    <PMID>25677599</PMID>
  </reference>
  <reference>
    <citation>Ben Assayag E, Tene O, Korczyn AD, Shopin L, Auriel E, Molad J, Hallevi H, Kirschbaum C, Bornstein NM, Shenhar-Tsarfaty S, Kliper E, Stalder T. High hair cortisol concentrations predict worse cognitive outcome after stroke: Results from the TABASCO prospective cohort study. Psychoneuroendocrinology. 2017 Aug;82:133-139. doi: 10.1016/j.psyneuen.2017.05.013. Epub 2017 May 18.</citation>
    <PMID>28549269</PMID>
  </reference>
  <reference>
    <citation>Dobkin BH. A Rehabilitation-Internet-of-Things in the Home to Augment Motor Skills and Exercise Training. Neurorehabil Neural Repair. 2017 Mar;31(3):217-227. doi: 10.1177/1545968316680490. Epub 2016 Nov 24.</citation>
    <PMID>27885161</PMID>
  </reference>
  <reference>
    <citation>Duncan PW, Sullivan KJ, Behrman AL, Azen SP, Wu SS, Nadeau SE, Dobkin BH, Rose DK, Tilson JK, Cen S, Hayden SK; LEAPS Investigative Team. Body-weight-supported treadmill rehabilitation after stroke. N Engl J Med. 2011 May 26;364(21):2026-36. doi: 10.1056/NEJMoa1010790.</citation>
    <PMID>21612471</PMID>
  </reference>
  <reference>
    <citation>Hiragami S, Inoue Y, Harada K. Minimal clinically important difference for the Fugl-Meyer assessment of the upper extremity in convalescent stroke patients with moderate to severe hemiparesis. J Phys Ther Sci. 2019 Nov;31(11):917-921. doi: 10.1589/jpts.31.917. Epub 2019 Nov 26.</citation>
    <PMID>31871377</PMID>
  </reference>
  <reference>
    <citation>Joy MT, Ben Assayag E, Shabashov-Stone D, Liraz-Zaltsman S, Mazzitelli J, Arenas M, Abduljawad N, Kliper E, Korczyn AD, Thareja NS, Kesner EL, Zhou M, Huang S, Silva TK, Katz N, Bornstein NM, Silva AJ, Shohami E, Carmichael ST. CCR5 Is a Therapeutic Target for Recovery after Stroke and Traumatic Brain Injury. Cell. 2019 Feb 21;176(5):1143-1157.e13. doi: 10.1016/j.cell.2019.01.044.</citation>
    <PMID>30794775</PMID>
  </reference>
  <reference>
    <citation>Lohse K, Bland MD, Lang CE. Quantifying Change During Outpatient Stroke Rehabilitation: A Retrospective Regression Analysis. Arch Phys Med Rehabil. 2016 Sep;97(9):1423-1430.e1. doi: 10.1016/j.apmr.2016.03.021. Epub 2016 Apr 22.</citation>
    <PMID>27109329</PMID>
  </reference>
  <reference>
    <citation>Zhou M, Greenhill S, Huang S, Silva TK, Sano Y, Wu S, Cai Y, Nagaoka Y, Sehgal M, Cai DJ, Lee YS, Fox K, Silva AJ. CCR5 is a suppressor for cortical plasticity and hippocampal learning and memory. Elife. 2016 Dec 20;5. pii: e20985. doi: 10.7554/eLife.20985.</citation>
    <PMID>27996938</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 5, 2021</study_first_submitted>
  <study_first_submitted_qc>March 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2021</study_first_posted>
  <last_update_submitted>March 5, 2021</last_update_submitted>
  <last_update_submitted_qc>March 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rehabilitation</keyword>
  <keyword>Exercise</keyword>
  <keyword>Maraviroc</keyword>
  <keyword>Randomized Control Trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Maraviroc</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

